Reduction of Hyaluronan-CD44–Mediated Growth, Migration, and Cisplatin Resistance in Head and Neck Cancer Due to Inhibition of Rho Kinase and PI-3 Kinase Signaling

Open Access
Publisher Website
Google Scholar
Abstract
Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignant neoplasm associated with major morbidity and mortality. The 3-year survival rate for patients with advanced-stage HNSCC who are treated with standard therapy is only 30% to 50%.1,2 Resistance to standard therapy continues to be a limiting factor in the treatment of HNSCC. Nearly 40% to 60% of patients with HNSCC subsequently develop locoregional recurrences or distant metastases.1,2

This publication has 24 references indexed in Scilit: